Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05352178 | Metastasis-directed Therapy for Oligorecurrent Prostate Cancer(SPARKLE) | recruiting | Phase 3 | 873 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05847348 | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | unknown | Phase 3 | 110 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Jul 3, 2024 |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03751124 | Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 229 | Myovant Sciences GmbHINDUSTRY | 8 | Jun 25, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06467097 | Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma(SABLOR) | recruiting | Phase 3 | 88 | Samsung Medical CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT06441110 | Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | recruiting | Phase 3 | 76 | Fujian Medical University Union HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05799248 | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | unknown | Phase 3 | 113 | MidLantic UrologyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT05622162 | Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7(MIP7) | unknown | Phase 3 | 106 | ITEL Telecomunicazioni SrlINDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT03412890 | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 477 | Myovant Sciences GmbHINDUSTRY | 9 | May 9, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT04684628 | 68Ga-PSMA PET/CT in Prostate Cancer | suspended | Phase 3 | 500 | University of SaskatchewanOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06350825 | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT01820858 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma(EC-01) | active not recruiting | Phase 3 | 300 | Ding MaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03940196 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | completed | Phase 3 | 540 | NovoCure Ltd.INDUSTRY | 13 | Mar 29, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT02145871 | A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy | completed | Phase 3 | 282 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases(ALADDIN) | recruiting | Phase 3 | 152 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04642027 | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy(PERYTON) | recruiting | Phase 3 | 538 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05627752 | Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | unknown | Phase 2 / Phase 3 | 120 | Zhongnan HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03388346 | 68Ga PSMA in Preprostatectomy Patients | completed | Phase 2 / Phase 3 | 22 | Michael Graham PhD, MDOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | terminated | Phase 3 | 23 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04644822 | Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. | completed | Phase 3 | 100 | Centre for Probe Development and CommercializationOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05189028 | Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer | unknown | Phase 3 | 290 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05564286 | Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer | completed | Phase 3 | 116 | Shantou University Medical CollegeOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01864096 | The Metformin Active Surveillance Trial (MAST) Study(MAST) | unknown | Phase 3 | 408 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01584258 | Prostate Advances in Comparative Evidence(PACE) | active not recruiting | Phase 3 | 2,205 | Royal Marsden NHS Foundation TrustOTHER | 4 | Jan 19, 2024 | clinicaltrials |
| NCT06211023 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | unknown | Phase 2 / Phase 3 | 520 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04887506 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | completed | Phase 3 | 107 | Tavanta TherapeuticsINDUSTRY | 8 | Jan 16, 2024 | clinicaltrials |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer | terminated | Phase 2 / Phase 3 | 46 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | terminated | Phase 3 | 74 | Chinese University of Hong KongOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | terminated | Phase 3 | 38 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | not yet recruiting | Phase 3 | 37 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT01394263 | Study of Histrelin Subdermal Implant in Patients With Prostate Cancer | completed | Phase 3 | 59 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT01697384 | Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer | completed | Phase 3 | 138 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06177015 | Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | recruiting | Phase 3 | 452 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jul 3, 2024source: clinicaltrials